032 A multicomponent skin-targeted COVID-19 vaccine elicits robust humoral and cellular immune responses

Abstract

Considerable progress has been made toward development of COVID-19 vaccines in the past year. However, there is still a need for painless, self-administered, shelf-stable, and efficacious SARS-CoV-2 vaccines to enable sustainable immunization programs against COVID-19. To address this need, we hypothesized that harnessing the immune-responsive cutaneous microenvironment using microarray patches (MAPs) to deliver integrated SARS-CoV-2 vaccine components would bring together biologic advantages of targeting the endogenous immune circuitry of the skin with a thermostable and user-friendly cutaneous vaccine delivery platform.